
http://researchrepository.murdoch.edu.au/27842

Copyright © Future Medicine
It is posted here for your personal use. No further distribution is permitted.
Topical treatment in pain medicine: from ancient remedies to modern usage

Philip M Finch*1 & Peter D Drummond2

1Perth Pain Management Centre, Perth, Western Australia, Australia
2Centre for Research on Chronic Pain & Inflammatory Diseases, Murdoch University, Perth, Western Australia, Australia
*Author for correspondence: pfinch@iinet.net.au

Abstract:
Over several millennia, substances have been applied to the skin for treatment of pain. Some ingredients are in current use; others have been discontinued. Mechanisms of action include interactions with nociceptive neural networks and inflammatory processes. Substances must penetrate the stratum corneum barrier and vehicles that enhance penetration have been developed. Topical drugs with links to the past include menthol, capsaicin, some opioids, local anaesthetic agents and non-steroidal anti-inflammatory drugs. Mandragora is also described as an example of a herbal remedy that has been discontinued due to its toxicity. The future for topical drugs is promising, with the advent of new drugs tailored for specific pain mechanisms and the development of both penetration enhancers and sterile preparation methods.

Key Words: Topical drugs, mechanisms, stratum corneum, antiquity, vehicles, receptors, current agents

Introduction
Over several millennia, substances have been applied externally for painful conditions but with variable success. In modern times, the mode of action of these ancient remedies has become clearer. Our Neolithic ancestors most probably used herbal remedies but records only appeared with the advent of cuneiform writing on clay tablets by the Sumerians (Third dynasty of Ur, c.3100 BCE)[1, 2], and later by the Egyptians writing on papyrus (Kahun c.1900 BCE and Ebers papyri c.1600 BCE).[3, 4] Pharmacopoeias of “bush medicines”, including...
analgesic applications may, however, have been in existence for much longer. Indigenous cultures have existed in Australia dating back at least 40,000 years.[5, 6] Recipes were initially passed on by oral tradition [7], but only appeared in the literature in recent times.[8] Similar ancient traditions of topical application for medicinal purposes can be found in Persian, Chinese, Indian, Central and South American cultures.[9] The use of herbal preparations continues to this day [10-12] and it is suggested that approximately 25% of modern medications are developed from plants. More than 85,000 plant species have been documented for medical use globally and many of them used topically.[13] This review will examine a number of substances, often with herbal ancestries, which have been applied topically over the past five thousand years. Some of these substances are still in use for the treatment of pain. Others, such as the topical application of Sciatica Cresses, listed in Culpepper’s Herbal for the treatment of sciatica, are confined to history and, thankfully, are no longer in use.

“The leaves but especially the root, taken fresh in summer time, beaten or made into a poultice or salve with old hog’s grease, and applied to the places pained with the sciatica, to continue thereon four hours if it be on a man, and two hours on a woman; the place afterwards bathed with wine and oil mixed together, and then wrapped with wool or skins, after they have sweat a little will assuredly cure not only the same disease in hips, huckle-bone, or other of the joints, as gout in the hands or feet, but all other old griefs of the head, (as inveterate rheums) and other parts of the body that are hard to be cured. And if of the former griefs any parts remain, the same medicine after twenty days, is to be applied again.” [14]

**Mechanisms for Topical Analgesia**

**Anatomy of nociception:** A dense network of nerve fibres that runs along the dermal-epidermal junction, supplies strands that project through the epidermis almost to the skin surface. These nerve fibres are ideally positioned to detect potential sources of injury to the skin. When activated, they signal pain – often described as a sharp stabbing sensation or a burning ache. They also coordinate an inflammatory response, initiated by release of vasoactive neuropeptides from the nerve terminals in the skin. Below we describe effects of the local
environment on nociceptive signalling, both under normal conditions and in inflammatory states and neuropathic pain. We also suggest possible mechanisms of analgesia for topically applied drugs.

**Illustration: Normal Human Skin**

**Propagation of nociception:** Nociceptive sensations are detected by slowly-conducting unmyelinated C-fibres and faster-conducting myelinated A-fibres, ranging in size from thinly myelinated A-delta fibres through to thicker, more heavily myelinated A-beta fibres.[15] The faster-conducting A-fibres lose their myelin sheath in the dermis, terminating as free nerve endings.[16] These nerve endings are exquisitely sensitive to chemical and thermal disturbances in the surrounding extracellular fluid. The subsequent propagation of neural impulses involves sequential opening of voltage-gated ion channels that permit passage of sodium, potassium, chloride and calcium through the neural membrane. In addition, many other ligand-gated channels regulate neural excitability (such as acid-sensing ion channels, transient receptor potential channels, and hyperpolarization-activated cyclic nucleotide-gated channels).[17] These mechanisms make neurons particularly sensitive to minor perturbations in their local environment and also provide many targets for topical drug manipulation.

**The inflammatory milieu:** After injury to the skin, sensory transduction and signalling is modulated by a plethora of receptors that respond to substances released from the bloodstream, from injured tissue, from resident cells such as fibroblasts, keratinocytes, Langerhans cells and mast cells, and from immune cells recruited to the site of injury. Together, these substances produce a milieu containing, among other ingredients, hydrogen ions, prostaglandins, cytokines, growth factors, noradrenaline, glutamate, bradykinin, serotonin, histamine and adenosine.[18] This inflammatory *milieu* can both directly activate and sensitize nerve endings to stimulation by acting on ion channels (for example hydrogen ions that operate on acid-sensing ion channels) or by altering second-messenger systems (by acting on G-protein-coupled metabotropic receptors) such as α-adrenoceptors). Externally applied topical drugs that modify this *milieu* or its targets can therefore act directly to reduce pain and inflammation.
Signal transduction: Sensory afferents interact with cutaneous cells that not only provide physical and trophic support but also contribute to signal transduction. For example, keratinocytes produce many of the receptors and transmitters expressed by neurons and, by this means, can communicate with neurons in a paracrine manner.[19, 20] This is important after nerve and tissue injury. For example, after limb fracture, neuropeptides and noradrenaline released from nerve terminals in the skin activate receptors on the surface of keratinocytes which, in turn, secrete high levels of inflammatory cytokines and nerve growth factor.[21, 22] These agents degranulate mast cells and sensitize cutaneous nociceptive neurons, thereby contributing to pain.[23] Topical drugs that penetrate the stratum corneum can act directly on this keratinocyte layer, possibly modifying its function.

Receptor targets for analgesia: Some of the excitatory receptors expressed on peripheral nerve fibres provide useful targets for analgesia. For example, the capsaicin receptor (vanilloid receptor 1) is a member of the transient receptor potential (TRP) family of receptors and is expressed on polymodal nociceptors.[24] Occupancy of this receptor or activation by heat or hydrogen ions, triggers sodium and calcium ion influx, generates action potentials and results in burning pain. Excessive influx of calcium ions can, however, evoke desensitization, which potentially is useful in pain management. Another TRP receptor, TRPM8 (the menthol receptor), is expressed both on cold-specific A-delta fibres and on cold-sensitive nociceptors.[25, 26] Low concentrations of menthol appear to primarily activate cold-specific fibres whereas higher concentrations activate nociceptors as well.[27] Like the capsaicin receptor, excessive influx of calcium ions into these cold-sensitive nociceptors is associated with desensitization and analgesia.[28]

Although many receptors exert excitatory effects on neural activity, others inhibit neural excitability and discharge (for example, μ-opioid receptors).[29] Under normal conditions, the opioid receptors are separated from agents in the extracellular fluid by the perineurium, an impermeable sheath with tight cellular junctions that enclose bundles of nerve fibres. This sheath, however, becomes
porous during inflammation, thereby increasing access to protected receptors for endogenous and topically applied opioids.[30]

**The effects of chronic inflammation:** The receptor and ion-channel profile alters dramatically during chronic inflammation and on nerve fibres that survive peripheral nerve injury. For example, inflammation triggers an increase in expression of glutamate receptors on nociceptive fibres [31, 32], thereby providing a target for ketamine, a glutamate (N-methyl-D-aspartate: NMDA) receptor antagonist. Similarly, an up-regulation of purinergic (P2X3) receptors after peripheral nerve injury profoundly influences neural excitability [33], in part via interaction with α1-adrenoceptors.[34, 35] An increase in the expression of α1-adrenoceptors on nerve fibres that survive partial nerve injury may also contribute to sympathetically maintained pain.[36, 37]

**Ion channels as further targets for analgesia:** Changes in the function or expression of ion channels in inflammatory and neuropathic pain conditions may also mediate pain. For example, an up-regulation of NaV1.7 channels during inflammation and in rare hereditary pain disorders increases nociceptor excitability and impulse generation.[17] Local anaesthetic agents such as lidocaine inhibit pain and hyperalgesia partly by acting in a non-selective manner on voltage-gated sodium channels, including NaV1.7.[38, 39]

**Penetrating the Stratum Corneum**

The stratum corneum, the outermost layer of the skin, provides a barrier to noxious chemicals, potential infective agents, physical insults and solar radiation from the outside world that is protective for the organism. The layer protects against water loss but also presents a physical barrier to the ingress of topical and transdermal drugs. The stratum consists of multiple layers of dead hydrated corneocytes arranged in interdigitating layers that are surrounded by a lipid matrix comprising approximately 20% by volume.[40] The microanatomy has been described as a “brick-and-mortar” structure.[41, 42] Illustration

It is not a perfectly uniform surface, varying in thickness at different parts of the body with the thickest layer on the soles of the feet. It is also perforated by hair follicles and sweat glands that can passively assist in the ingress of drugs from
the exterior. The skin is a complex structure as unwanted influences that cannot be physically kept on the exterior are subsequently neutralised and attacked by the immune system or degraded by enzymatic reactions.[40] Various techniques are employed to improve the penetration of drugs through the outer layers of the skin. These include physical formulation and delivery methods. Physical methods include low frequency ultrasound, which disturbs the lipid matrix, radiofrequency energy formation of microchannels or electrophoretic assisted penetration. Even removal of the outer horny layer can be employed using chemical peels and dermabrasion.[43] Formulation techniques are the most commonly applied methods for enhanced penetration of drugs. The barrier to the ingress of drugs is reversibly reduced by agents, such as the lipid disrupting aprotic solvent dimethylsulphoxide (DMSO) [44] and the liposome, pleuronic lecithin organogel (PLO).[45, 46] Liposomes have been extensively studied since their discovery in the 1960s.[47] They comprise a lipid bilayer with the hydrophobic chains of the lipids forming the bilayer and the polar head groups of the lipids orientated towards the extra vesicular solution and the inner cavity.[48] Liposomes help localise topical drugs at their desired site of action or improve the penetration of transdermal drugs into the systemic circulation without causing skin irritation or harm.[49-52] Other proprietary liposomal preparations include Lipoderm® and Vanpen® that have the capacity to deliver multiple drug combinations through the skin.[53-55] Despite the apparent harmless nature of topical applications, contact dermatitis can occur after the application of topical drugs or their vehicle components.[56] There can be irritant and allergic contact dermatitis or contact urticarial. Patch testing is used to ascertain the culprit allergen.[57] At this point, the distinction between topical and transdermal should be emphasised. There are several effective transdermal preparations such as transdermal fentanyl and buprenorphine, whereby the active ingredient gains access to the systemic circulation but by the transdermal route. Topical applications, however, such as the application of a lidocaine patch for post herpetic neuralgia, reduce nociception by local skin mechanisms but achieve minimal systemic levels. Although neuropathic pain states can be improved by
achieving systemic levels of lidocaine, this is not the main aim of this topical application.

**Historical Use of Topical Drugs**

There have been a number of reviews of the use of topical agents, in particular in the management of neuropathic pain.[58-62] The size of this review precludes an exhaustive coverage of this topic. The reviews by Zur, Sawynok, Argoft and others [58-62] take a wider view of current topical agents than is possible in this paper. This review has included topical agents with historical links and current agents with a significant background literature. A few substances have ancient traditions and some of particular interest have been selected for discussion. Some agents have been employed over many centuries but have disappeared from clinical use, while others such as amitriptyline, clonidine and ketamine are the creation of modern times.

**Menthol:** The use of menthol stretches back into antiquity. It is a naturally occurring plant extract from several members of the plant genus *Mentha (Mint)* [63] but has been chemically synthesised in modern times. Menthol features in the Ebers papyrus (1550 BCE) as a remedy for stomach ailments [4] and there are claims of its cultivation for medicinal use in Japan over 2000 years ago.[63] Known in ancient Greece, the herb is named after the mythical beauty Minthe. The pungent sweet smelling mint was used in hospitality such as the fermented barley drink called the kykeon and in funerary rites.[64] Menthol is also included amongst a number of valuable herbs in the biblical indictment of the Pharisees (Luke 11:42). Peppermint appears in the London Pharmacopoeia in 1721 and menthol, the active ingredient, was first isolated as a compound by the Dutch botanist Gambius in 1771.[65]

Menthol (also known as mint camphor) is experiencing a renaissance as a topical analgesic agent. As well as providing a subjective cooling effect, it acts as a weak opioid agonist and weak sodium channel blocker.[66, 67] It is used in dermatology as an antipruritic agent, as a food additive in chewing gum and to flavour toothpaste and cigarette smoke. Menthol is a cyclic terpene alcohol acting on the transient receptor potential melastatin 8 receptor (TRPM8), a low
temperature sensing receptor in the skin and mucosa, (8-28°C) [68, 69] where it imparts a cool sensation. Capsaicin, in contradistinction, was the first of the transient receptor potential family to be identified. Menthol has several desirable qualities as well as its actions as a topical antipruritic agent, including antibacterial and antifungal activity.[70] It has been shown to enhance penetration of the stratum corneum in both animal and human models [71] possibly through disruption of the lipid layer of the stratum corneum.[72] Topical menthol has analgesic actions that make it a beneficial inclusion in over-the-counter pain relief applications. In low concentrations (<1%) menthol depresses cutaneous nociception and perhaps even desensitises nociceptive C fibres.[73] In high concentrations (>30% menthol can act as an irritant.[74, 75] As menthol acts on voltage-gated channels in neuronal structures, it also has a weak local anaesthetic effect.[76, 77] There are many possible uses for this topical agent, discussed in depth elsewhere.[78-81] Other substance acting on TRPM8 receptors include eucalyptol and the potent synthetic Icilin.[82]

**Capsaicinoids:** Capsaicin is the principal active component in hot chilli peppers of the plant genus *Capsicum*, which have their origin in the Americas. Chilli peppers were probably cultivated as a dietary condiment dating back over 6000 years.[83] Limited Mayan hieroglyphs (The Maya, circa 750BCE -1524 CE) have survived and have proved difficult to decipher as much written material was burnt in 1562. It is unknown if written descriptions of the medicinal use of chilli peppers exist from this period. Later, Aztec physicians in Central America may have used chilli pepper to treat painful conditions such as toothache.[84] Chilli pepper was probably transported to the Old World by Columbus and thence to Asia by Portuguese navigators in the 16th century. Other capsaicinoids known to antiquity include euphorbium whose active ingredient is the potent capsaicinoid resinifratoxin, extracted from the latex of *Euphorbia resinifera*.[85] The physician Euphorbius may have used resinifratoxin-containing salves to treat the arthritic pains of the Emperor Augustus 63 BCE -14 CE, but it was probably in use well before this time.[85] Previously used as an emetic and violent purgative, euphorbium has been employed as a rubefacient for painful joints,[86, 87] It was listed in 1578 for
treating toothache and more recently for intractable bone pain.[86] Topical plant extracts containing capsaicinoids such as Bhut jolokia, indigenous to Northeast India, are still in use to treat arthritic pains.[87] Bhut jolokia is recorded as being 900.5 times as hot as Tabasco sauce.[88] One wonders what effect such a powerful capsaicinoid would have on the gastro-intestinal tract, if ingested. Capsaicin activates the transient receptor potential vanilloid receptor (TRPV1), an excitatory ion channel which is also activated by higher temperatures >43°C and is sensed as being hot.[24] Capsaicin has been extensively studied as a topical agent for the past three decades. As a low concentration, 0.025-0.075%, over-the-counter preparation (Zostrix), capsaicin has been prescribed for a number of conditions including post herpetic neuralgia. More recently it has also been marketed as an 8% patch (Qutenza) with effects lasting many weeks.[89] As a TRPV1 agonist, capsaicin induces a refractory period in nerve terminals expressing TRPV1 and in higher concentrations causes long term neuronal “defunctionalisation”. [90, 91] A single application of capsaicin 8% to the skin can diminish skin hypersensitivity in neuropathic pain states for periods as long as three months, reducing the issue of poor patient compliance with the weaker preparations that require multiple applications.[89, 92] The application of the 8% patch can be intensely painful and is often applied under local anaesthesia. Targeting TRP channels on nociceptor neurons in the skin is an attractive strategy for pain control as it can modify the peripheral pain pathway.[93] The use of capsaicin preparations as a topical application for neuropathic pain states such as post herpetic neuralgia has been the subject of several Cochrane reviews of the supporting evidence. The author’s concluded that repeated application of low dose (0.075%) capsaicin was without meaningful effect beyond placebo and that prior studies had not convincingly demonstrated efficacy. The use of low dose topical capsaicin commonly caused skin irritation leading to withdrawal.[94] The use of high dose capsaicin for neuropathic pain states including post herpetic neuralgia and HIV-neuropathy provided good relief of pain for about one patient in eight (NNT=8.8). It was also concluded that high dose capsaicin was probably less effective than gabapentin or pregabalin.[95]
**Opioids:** Opium obtained from *Papaver somniferum* was well known to the ancients and most probably was cultivated by the Sumerians (c. 3000 BCE) [96] and ancient Egyptians. Of particular historical interest is the use of transdermal patches of opioid in ancient Greece. Olympic victor’s dark ointment (OVDO) mentioned by Galen (c. 129-200 CE), was an opium-based patch that was applied to the skin of athletes. It dried rapidly to cover a localised area and recent measurements of the transdermal transfer of morphine indicate a transfer comparable to 25% of modern transdermal patches.[97, 98] It may have, therefore, acted both systemically to reduce pain and by local effects, acting on inflammatory mechanisms. The Latin description for its use by Galen of Pergamum (130-200 CE) and its English translation states:

*Facit ad maximos Dolores - useful for extreme pain*

*Nam ftatim liberat - providing relief immediately.*[97]

Perhaps this was an early indicator for a more recent and disgraceful practice in sport.

The modern contemporary use of opioids as topical agents is somewhat marginal and is mainly confined to the management of skin and corneal ulceration, having some local anti-inflammatory actions.[99, 100] The increased expression of opioid receptors on nociceptors in inflammatory pain states provides a logical target for topically applied opioids. There are indications that topically applied opioids can ameliorate the pain of skin ulcers and post radiation mucositis [99, 101-103], but the numbers in various clinical trials have been low and further evidence is needed. Their usage is perhaps best seen in the palliative care field where they can relieve inflammatory pain without significant systemic side effects.[99] Topically applied morphine can be applied in gels and oral rinses prepared by pharmacies over a range from 0.1-2% concentration.[104, 105] Other opioids employed in topical applications include methadone [106], fentanyl [100], and oxycodone.[107]

**Mandragora:** Employed as a topical analgesic agent and central sedative that is no longer used due to its toxic effects, mandragora (mandrake) has an ancient and fascinating history. *Mandragora officinarum* is native to the eastern Mediterranean and contains the active ingredients scopolamine and
atropine. It has even been termed the “Anesthetic of the Ancients”. Hannibal (247-182 BCE) used it to drug his opponents during the Battle of Carthage (200 BCE). Mentioned in the Bible, Genesis 30:14-24, mandrake subsequently achieved a reputation amongst medieval Christians for enhancing fertility. It was advocated in the writings of Flavius Josephus (c. 37-101) that a dog be employed to pull out the root, thus avoiding any lethal effects on humans from hearing the scream of the mandrake plant as it was pulled from the ground. Mandrake also had demonic associations and was even used in the indictment of Joan of Arc in 1431 CE. The use of mandrake most probably produced sufficient topical analgesia and sedation for the physician Hua Tuo (110-207 CE) to debride an arrow wound in General Guan Yu after the battle of Fan city but allowing him to continue playing chess, talk and laugh as if nothing had happened. More recently, it featured in several of Shakespeare’s works, such as *Cleopatra*, act 1, scene v: “Give me to drink Mandragora—that I might sleep out this great gap of time. My Antony is away.” Mandragora was mixed with plant extracts such as opium and henbane (*Hyoscyamus niger*, another tropane alkaloid which can also be applied topically for “obstinate rheumatic pains”), to produce sedation for surgical procedures. It was evaporated into a sea sponge and the preparation known as *Spongia somnifera* was employed extensively until its use faded with the advent of general anaesthesia in the nineteenth century CE. The potency and toxicity of this plant extract varied considerably depending on its mode of extraction. With no attempt at purification or precise dosing, *Spongia somnifera* could cause death from respiratory and circulatory depression.

**Cocaine**: Topical local anaesthetic agents currently play a significant part in treating some neuropathic pain conditions. Cocaine derived from coca leaves, *Erythroxylum coca* was first used as a topical local anaesthetic agent on the cornea of a frog and then a human by Karl Koller in 1884, after discussions with his friend Sigmund Freud, who was interested in cocaine for its effects on his patient’s mood. The origins of coca are ancient, however, dating back to the pre-Moche period (100-750 CE) in Peru and the Eastern Andes. The coca leaf
was chewed or used to make tea to combat fatigue and altitude sickness. Traces of coca have been found in mummified human cadavers dating back 3000 years [115] and probably millennia before this. The French naturalist Joseph de Jussieu (1704-1779) introduced coca leaf into Europe, and cocaine was isolated from the mix of alkaloids from the coca plant by Gaedecke in 1855 who called it Erythroxyline and subsequently extracted and purified by Niemann in 1860. It became popular as a stimulant in the 19th century CE and was even included as an ingredient in early formulations of Coca-Cola until 1903 when it was withdrawn.[116] Cocaine’s addictive qualities were recognised in the nineteenth century and it became a widely prohibited substance in the early 20th century CE. The use of unprocessed coca leaves is still lawful in some South American countries.

Local anaesthetic agents have become one of the mainstays of modern surgery. Topical local anaesthetic agents are also finding a place in the management of some pain states, in particular neuropathic pain. The use of a 5% lidocaine patch to treat neuropathic pain states, especially post herpetic neuralgia, has received particular attention and is the subject of several reviews.[117-119] The use of a lidocaine patch has also been the subject of a 2008 Cochrane review, which concluded that three studies into its efficacy had sufficient scientific rigour to be included but provided insufficient evidence to support its use as a first-line treatment of post herpetic neuralgia.[120] More recent reviews would suggest otherwise. For example, a review by Wolff et al. concluded that a 5% lidocaine topical patch is more effective than capsaicin and pregabalin.[119] Lidocaine has also been used as a topical spray for dressing changes, for pain associated with peripheral blood flow disorders, and post herpetic neuralgia.[121-123] Safety issues have been considered in a 2002 pharmacokinetic study that considered the 5% lidocaine patch to be safe, only causing mild skin erythema and low plasma lidocaine levels [124], but a single case report has concluded that lidocaine toxicity is possible when multiple forms of topical application are used.[125]

**Topical non-steroidal anti-inflammatory drugs (NSAIDs):** Extracts from willow trees and other salicylate containing plants also have their origins in
antiquity, possibly dating back to the Sumerians and ancient Egyptians in the
treatment of fevers. The active ingredient, acetylsalicylic acid (aspirin) was
synthesised by the Bayer Company in 1897.[126] Salicylates are largely
administered orally but there has been some topical use of aspirin containing
solutions of chloroform or ether in the treatment of post herpetic neuralgia.[127]
Modern NSAID use commenced with the introduction of indomethacin in
1962.[128] Significant gastrointestinal adverse effects from the oral
formulations of NSAIDs have been encountered and in an effort to reduce these
effects, various topical preparations of NSAIDs have been developed. In a recent
comprehensive review of these topical preparations, it was concluded that
topical NSAIDs were superior to placebo and had similar outcomes to oral
NSAIDs in the treatment of both acute and chronic musculoskeletal injuries.[129]
Gastrointestinal side effects were less with the topical group but minor skin
reactions were more frequent. Several formulations, discussion concerning
penetration enhancers and guidelines for use have been published regarding this
group of topical agents.[126, 130-132] Topical versus oral NSAIDs can be
particularly advantageous in the elderly and have been recommended as a first-
line treatment for osteoarthritis in this age group.[133]

**Topical Agents of the Modern Era: amitriptyline, clonidine and ketamine:**

**Amitriptyline**, a tricyclic antidepressant, has a number of actions including its
ability to inhibit the reuptake of noradrenaline and serotonin. It has been shown
to block various voltage gated ion channels including Na⁺, K⁺ and Ca⁺⁺ [134,135]
and several receptors including α₂ adrenoceptor, cholinergic, NMDA and
histamine [134-136] pointing to a use as a topical agent with peripheral nerve
fibre effects.[137] Although not effective in every trial [138], amitriptyline at
concentrations between 2-10%, along with some other antidepressant agents
has been successfully used as a topical agent in a number of neuropathic pain
states including complex regional pain syndrome (CRPS), multiple sclerosis and
vulvodynia.[139-141] Amitriptyline has been employed as a sole agent or in
combination with other topical agents such as ketamine and baclofen.[142-147]
Although the topical application of antidepressant drugs can reduce their
unwanted central side effects, this form of administration can occasionally lead to adverse toxicity.[148]

**Clonidine** is an α2-adrenergic receptor agonist used in the treatment of hypertension. Side effects that include somnolence and hypotension have limited its use in treating neuropathic pain states. It has, however, been found to be antinociceptive if applied to the skin and successfully used in the reduction of hyperalgesia in patients with sympathetically maintained pain [149] and painful diabetic neuropathy.[150] Blood levels of clonidine in this later RCT were below the level of detection suggesting that the effects of this topical agent were peripherally mediated and probably a direct effect on epidermal nociceptors. Typically, it is applied as a patch (30mcg/cm²/day) or as a 0.1-0.2% solution.

**Ketamine**, which blocks glutamate N-methyl-D-aspartate (NMDA) receptors on peripheral nerve fibres, can reduce nociceptive transmission.[151] It has been studied as a topical analgesic agent and has been the subject of many trials, case reports and reviews.[152-154] It can be used as a gel or cream with relative safety and apparent efficacy mainly for localised neuropathic pain states at concentrations up to 20%.[153] There have also been a number of reports of its use in combination with other agents such as amitriptyline, baclofen and gabapentin but with mixed results.[141, 142, 147] Long-term effects on the urinary tract [155] may be circumvented by the use of topically applied ketamine, which results in low plasma levels of the drug.[156] Nevertheless, as with some other topical drugs, inappropriate or excessive use can lead to significant toxicity.[157]

**Combinations** of drugs for topical application can be used for treatment of some pain states -for example: ketamine 10% with amitriptyline 4% in Vanpen® penetrant for post herpetic neuralgia or amitriptyline 2-4% combined with gabapentin 6-10% with oestradiol 0.01% for vulvodynia are used in clinical practice but the rationale for the selection of agents, their percentage composition and the vehicle used is not clear. A recent review by Zur 2014 considers such mixtures in depth.[62] Such tailored recipes are controversial and can attract the criticism of being entrepreneurial.

**Conclusion and Future Perspectives**
A number of substances have been applied to the skin and mucosa for painful conditions over thousands of years but without any understanding of their pharmacological actions. The inevitable toxic effects of some substances have led to their withdrawal from use. Others seen to have beneficial effects continue to be applied to this day, but with considerable refinement in their use and understanding of the mechanisms involved. As the knowledge of peripheral pain pathways has increased, so has the tailoring of drugs to act on these mechanisms of nociception. After penetration of the skin they are able to act directly on the initiating factors that lead to pain. Most advantageously, the use of topical drugs has reduced the adverse effects of many of these agents that are also administered systemically. This can be of great benefit to the frail and elderly. The future for the topical application of drugs is bright. In addition to improved targeting of specific pain mechanisms with new drugs or different formulations of existing ones, enhanced penetration agents will improve delivery of these agents. “Topicals” prepared in laminar flow facilities will allow application to areas of broken skin or mucosa without encouraging infection. Alternative routes for topical applications of drugs will be developed including the rectal mucosa, vulva and the oropharynx. Lastly, as best practice for topical drug application becomes clearer from a pharmacological perspective, so will the selection of suitable patients and pain states that are likely to respond.

Executive Summary:

- The topical application of drugs that act locally in the skin provides an attractive strategy for treating pain, reducing the potential systemic side effects of oral or parenteral administration.
- Some agents used since antiquity have been discontinued but others are used to this day.
- Mechanisms of action include effects on skin neural networks and inflammatory processes.
- The stratum corneum layer of the skin presents a significant barrier to the absorption of drugs. Penetration enhancers have evolved that improve this absorption.
- Menthol, used in ancient Egypt, is experiencing a renaissance. Acting on the TRPM8 receptor, it imparts a cool sensation to the skin and mucosa.
- Capsaicin, acting on the TRPV1 receptor, also has an ancient lineage being derived from chilli peppers. It imparts a sensation of heat to the skin and mucosa.
- Opioids, described for topical use for athletes in ancient Greece, have more recently been employed in the treatment of painful skin and corneal ulceration.
- Mandragora (Mandrake) is a topical plant extract with a long history of use that has been discontinued due to its unpredictable toxicity.
- Local anesthetic agents discovered in the nineteenth century, have their origin in cocaine from the Americas. The 5% lidocaine patch has some utility in treating neuropathic pain states such as post herpetic neuralgia.
- The use of topical NSAIDS follows in the footsteps of the application salicylate containing plants by ancient Sumerians and Egyptians. Topically applied NSAIDs show efficacy in the treatment of painful musculoskeletal structures comparable to oral ingestion but without the gastro-intestinal side effects.
- Topical amitriptyline, clonidine and ketamine are examples of modern topical agents, employed principally for neuropathic pain, that are supported by a significant literature.
- The future for topical drugs is encouraging, as the mechanisms of pain have become better understood. The development of new topical preparations, penetration enhancers and sterile techniques of preparation have all contributed to this expanding field.

References:


142. Lehman JS, Sciallis GF: Effective use of topical amitriptyline hydrochloride 2.5% and ketamine hydrochloride 0.5% for analgesia in refractory proctodynia. *J Drugs Dermatol.* 7(9), 887-889 (2008).


References of Interest:


7. Argoff CE: Topical analgesics in the management of acute and chronic pain. *Mayo*
Illustration: Human Skin: A section of normal human skin demonstrating the principal layers. Nerve fibres (green), including nociceptors have been stained by PGP9.5, which is a pan neuronal immunohistochemical marker. (From unpublished work by Finch P and Drummond D)